Treatment of VLCAD-Deficient Patient Fibroblasts with Peroxisome Proliferator-Activated Receptor δ Agonist Improves Cellular Bioenergetics

• Published in: Cells (Basel, Switzerland) Vol. 11; no. 17; p. 2635
• Main Authors: D'Annibale, Olivia M, Phua, Yu Leng, Van't Land, Clinton, Karunanidhi, Anuradha, Dorenbaum, Alejandro, Mohsen, Al-Walid, Vockley, Jerry
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24.08.2022; MDPI
• Subjects: ACADs; Acyl-CoA dehydrogenase; Acyl-CoA Dehydrogenase, Long-Chain - genetics; acyl-CoA dehydrogenases; Adenosine Triphosphate - metabolism; Adolescent; Adult; Agonists; Agonists (Biochemistry); Bioenergetics; Cardiomyopathy; Cell lines; Child; Children; Cholesterol; Clinical trials; Congenital Bone Marrow Failure Syndromes; Dehydrogenases; Diet; Energy Metabolism; Enzymatic activity; fatty acid oxidation; Fatty acids; Fibroblasts; Fibroblasts - metabolism; Gene expression; Genotypes; Glucose; Health aspects; Humans; Hypoglycemia; Insulin; Kidneys; Life sciences; Lipid Metabolism, Inborn Errors; Lipids; Medical screening; Metabolism; Missense mutation; Mitochondrial Diseases; Muscular Diseases; Mutation; Myopathy; Obesity; Oxidation; Oxidative phosphorylation; Oxidative stress; Oxidoreductases; Oxygen consumption; Patients; Phosphorylation; PPAR delta - metabolism; PPARs; Proteins; Regulation; REN001; Rhabdomyolysis; Statistical analysis; Triglycerides; VLCAD deficiency; United States; United States > US; REN001; acyl-CoA dehydrogenases; fatty acid oxidation; cellular bioenergetics; ACADs; PPARs; VLCAD deficiency
• DOI: 10.3390/cells11172635
• ISSN: 2073-4409

Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency is an autosomal recessive disease that prevents the body from utilizing long-chain fatty acids for energy, most needed during stress and fasting. Symptoms can appear from infancy through childhood and adolescence or early adulthood, and include hypoglycemia, recurrent rhabdomyolysis, myopathy, hepatopathy, and cardiomyopathy. REN001 is a peroxisome-proliferator-activated receptor delta (PPARδ) agonist that modulates the expression of the genes coding for fatty acid β-oxidation enzymes and proteins involved in oxidative phosphorylation. Here, we assessed the effect of REN001 on VLCAD-deficient patient fibroblasts. VLCAD-deficient patient and control fibroblasts were treated with REN001. Cells were harvested for gene expression analysis, protein content, VLCAD enzyme activity, cellular bioenergetics, and ATP production. VLCAD-deficient cell lines responded differently to REN001 based on genotype. All cells had statistically significant increases in gene expression. Small increases in VLCAD protein and enzyme activity were observed and were cell-line- and dose-dependent. Even with these small increases, cellular bioenergetics improved in all cell lines in the presence of REN001, as demonstrated by the oxygen consumption rate and ATP production. VLCAD-deficient cell lines containing missense mutations responded better to REN001 treatment than one containing a duplication mutation in . Treating VLCAD-deficient fibroblasts with the REN001 PPARδ agonist results in an increase in VLCAD protein and enzyme activity, and a decrease in cellular stress. These results establish REN001 as a potential therapy for VLCADD as enhanced expression may provide a therapeutic increase in total VLCAD activity, but suggest the need for mutation-specific treatment augmented by other treatment measures.